SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Predictive Oncology Inc. (AGPU) (CIK 0001446159) (AGPU) — Apr 13, 2020

Predictive Oncology Inc. (AGPU) (CIK 0001446159)
Date: April 13, 2020 · CIK: 0001446159 · Accession: 0000000000-20-003156

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237581

Date
April 13, 2020
Author
Bob Myers
Form
UPLOAD
Company
Predictive Oncology Inc. (AGPU) (CIK 0001446159)

Letter

April 13, 2020 Bob Myers Chief Financial Officer Predictive Oncology Inc. 2915 Commers Drive, Suite 900 Eagan, Minnesota 55121 Re:Predictive Oncology Inc. Registration Statement on Form S-3 Filed April 6, 2020 File No. 333-237581 Dear Mr. Myers: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Martin R. Rosenbaum, Esq.

Show Raw Text
April 13, 2020
Bob Myers
Chief Financial Officer
Predictive Oncology Inc.
2915 Commers Drive, Suite 900
Eagan, Minnesota 55121
Re:Predictive Oncology Inc.
Registration Statement on Form S-3
Filed April 6, 2020
File No. 333-237581
Dear Mr. Myers:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Martin R. Rosenbaum, Esq.